Welcome to our dedicated page for Immatics N.V news (Ticker: IMTX), a resource for investors and traders seeking the latest updates and insights on Immatics N.V stock.
Immatics N.V. develops clinical-stage cancer immunotherapies built around T-cell receptor biology, with a stated focus on precision targeting of PRAME across solid tumors. News about IMTX most often covers clinical updates for PRAME-directed cell therapies and TCR bispecifics, including anzu-cel (anzutresgene autoleucel, IMA203), IMA203CD8, IMA402 and IMA401 MAGEA4/8. Company announcements also cover presentations at oncology meetings such as ASCO, AACR and ESMO, where Immatics reports safety, dose-escalation and anti-tumor activity data across melanoma, ovarian cancer, synovial sarcoma and other PRAME-positive cancers.
Recurring updates include financial results, business updates, collaboration activity, clinical and regulatory disclosures, leadership changes, shareholder voting matters and capital-structure disclosures for the Nasdaq-listed biotechnology company.
Immatics N.V. (NASDAQ: IMTX) has announced an upcoming oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024. The presentation will showcase the first proof-of-concept clinical data for TCER® IMA401, their next-generation, half-life extended TCR Bispecific molecule targeting MAGEA4/8.
The presentation, titled "Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR Bispecific, in Phase 1 dose escalation," will be delivered by Dr. Martin Wermke from University Hospital Dresden, Germany. It is scheduled for September 16, 2024, at 11:25 CEST in the Granada Auditorium - Hall 6, as part of the Investigational Immunotherapy session.
Full abstracts will be available on the ESMO website on September 9, 2024, at 00:05 CEST.
Immatics (NASDAQ: IMTX) reported its Q1 2024 financial results and provided a business update, including clinical data from their ongoing Phase 1 trial of ACTengine® IMA203 targeting PRAME. The trial showed a 55% confirmed objective response rate in heavily pre-treated metastatic melanoma patients, with tumor shrinkage in 87% and a median response duration of 13.5 months. IMA203 maintained a favorable safety profile. A Phase 2/3 trial is planned for 2024.
The company also completed a $201.5 million public offering in January 2024, ending the quarter with $609.7 million in cash and equivalents, funding operations into 2027. Q1 2024 revenues were $32.8 million, largely due to a terminated collaboration, while net loss narrowed to $3.4 million from $21.3 million in Q1 2023. Upcoming milestones include updates on IMA203, IMA203CD8, and TCER® programs in 2H 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.